Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Collegium Pharmaceutical, Inc. - Common Stock (NQ:COLL)

29.64 -0.07 (-0.22%)
Streaming Delayed Price Updated: 1:57 PM EDT, Mar 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Collegium Pharmaceutical, Inc. - Common Stock

< Previous 1 2 3 Next >
Forecasting The Future: 4 Analyst Projections For Collegium Pharmaceutical
Via Benzinga
Q4 Earnings Highs And Lows: Royalty Pharma (NASDAQ:RPRX) Vs The Rest Of The Branded Pharmaceuticals Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX)... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
Collegium Pharmaceutical’s (NASDAQ:COLL) Q4 Sales Top Estimates, Stock Jumps 14.1%
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 21.5% year on year to $181.9 million. The company... 
Via StockStory
Earnings Scheduled For February 27, 2025
Via Benzinga
Collegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expect
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be reporting earnings tomorrow after the bell. Here’s what to look for. 
Via StockStory
A Preview Of Collegium Pharmaceutical's Earnings
Via Benzinga
The Analyst Landscape: 4 Takes On Collegium Pharmaceutical
Via Benzinga
The Analyst Verdict: Collegium Pharmaceutical In The Eyes Of 4 Experts
Via Benzinga
Collegium's Revenue Outlook And CNS Expansion Signal Undervalued Opportunity, Says Needham
Needham analyst upgrades Collegium Pharmaceutical to Buy with a $46 target, citing strong 2025 guidance, growth potential, and undervaluation. 
Via Benzinga
S&P Global To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Dr. Reddy's Stock Hit All-Time High Last Month. Ready To Climb Again?
Dr. Reddy's Labs sees its Relative Strength Rating enter the 80-plus level. 
Via Investor's Business Daily
Organon Stock Sees Relative Strength Rating Rise To 91
On Tuesday, Organon[ stock hit an key technical milestone, seeing its Relative Strength Rating jump to 91, up from 88 the day before. 
Via Investor's Business Daily
Organon Stock Earns Relative Strength Rating Upgrade; Hits Key Threshold
On Tuesday, generic drug maker Organon stock had its Relative Strength (RS) Rating upgraded to 83, up from 78 a day earlier. 
Via Investor's Business Daily
Demystifying Collegium Pharmaceutical: Insights From 4 Analyst Reviews
Via Benzinga
Critical Insights From Collegium Pharmaceutical Analyst Ratings: What You Need To Know
Via Benzinga
Where Collegium Pharmaceutical Stands With Analysts
Via Benzinga
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Beats Revenue for Q2 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
In a market where value is scarce, NASDAQ:COLL offers a refreshing opportunity with its solid fundamentals.
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
NASDAQ:COLL is an undervalued gem with solid fundamentals.
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Dr. Reddy's Labs Stock Sees Improved Technical Strength
On Friday, Dr. Reddy's Labs ADR stock earned an upgrade to its Relative Strength (RS) Rating, from 66 to 76. 
Via Investor's Business Daily
7 Biotech Stocks to Buy on the Dip: June 2024
With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. 
Via InvestorPlace
NASDAQ:COLL appears to be flying under the radar despite its strong fundamentals.
COLLEGIUM PHARMACEUTICAL INC (NASDAQ:COLL) is an undervalued gem with solid fundamentals. 
Via Chartmill
Recap: Collegium Pharmaceutical Q4 Earnings
Via Benzinga
Analyst Expectations For Collegium Pharmaceutical's Future
Via Benzinga
Why Collegium Pharmaceutical Shares Are Gaining Today
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial  
Via Benzinga
COLL Stock Earnings: Collegium Pharmaceutical Beats EPS, Misses Revenue for Q1 2024
COLL stock results show that Collegium Pharmaceutical beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Nasdaq Composite falling around 150 points on Wednesday. Shares of TDCX Inc. (NYSE: TDCX) rose sharply during Wednesday’s session after it disclosed receiving a... 
Via Benzinga
Topics Stocks
Exposures US Equities
Recap: Collegium Pharmaceutical Q3 Earnings
Via Benzinga
Needham Maintains Buy Rating for Collegium Pharmaceutical: Here's What You Need To Know
Via Benzinga
Atlassian, Universal Display, Booking, Dropbox And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 150 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.